PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Detailed View

Summary Gut microbes (genus: Prevotella) increase Methotrexate's activity.
Methotrexate (PubChem CID: 126941)
Prevotella (Tax ID: 838)
increase activity
The dihydrofolate reductase (DHF) inhibitor, methotrexate, is widely used to treat rheumatoid arthritis. Methotrexate resistance in some patients may be due to the high abundance of Bacteroides in the gut microbiota. Patients with gut microbiotas characterized by high abundance of Prevotella vs. low abundance of Bacteroides, are better responders to oral methotrexate therapy. The abundance of these genes, suggests a possible DHF reductase enzymatic activity, which competes with methotrexate binding site and metabolism. Bacterial DHF reductase was suggested to compete with methotrexate binding site and metabolism, but the absence of such enzyme in Prevotella in contrast of Bacteroides explains why the former increases the drug action while the latter inhibits it.

Browse Drug-Microbiome Relationship